A5050393463- Sepsis Diagnosis and Treatment
- Respiratory Support and Mechanisms
- Intensive Care Unit Cognitive Disorders
- Pneumonia and Respiratory Infections
- Organ Transplantation Techniques and Outcomes
- Nosocomial Infections in ICU
- Liver Disease and Transplantation
- Antibiotics Pharmacokinetics and Efficacy
- Abdominal Trauma and Injuries
- Anesthesia and Sedative Agents
- Pancreatitis Pathology and Treatment
- Hemodynamic Monitoring and Therapy
- COVID-19 Clinical Research Studies
- Streptococcal Infections and Treatments
- Adrenal Hormones and Disorders
- Cardiac Arrest and Resuscitation
- Poisoning and overdose treatments
- Antibiotic Resistance in Bacteria
- Immune Response and Inflammation
- Inhalation and Respiratory Drug Delivery
- Long-Term Effects of COVID-19
- Antimicrobial Resistance in Staphylococcus
- Renal function and acid-base balance
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Venous Thromboembolism Diagnosis and Management
Cliniques Universitaires Saint-Luc
2016-2025
UCLouvain
2014-2023
The University of Queensland
2023
Antwerp University Hospital
2006-2023
University of Mons
2023
Ghent University Hospital
2023
University of Antwerp
2023
Vrije Universiteit Brussel
2023
UCLouvain Saint-Louis Brussels
2004-2022
The Coordinating Center
2022
Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin produced dose-dependent reductions in the levels of markers coagulation inflammation patients with severe sepsis. this phase 3 trial, we assessed whether treatment reduced rate death from any cause among
Hydrocortisone is widely used in patients with septic shock even though a survival benefit has been reported only who remained hypotensive after fluid and vasopressor resuscitation whose plasma cortisol levels did not rise appropriately the administration of corticotropin.In this multicenter, randomized, double-blind, placebo-controlled trial, we assigned 251 to receive 50 mg intravenous hydrocortisone 248 placebo every 6 hours for 5 days; dose was then tapered during 6-day period. At 28...
In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis a high risk of death. The FDA required study to evaluate efficacy DrotAA low death.We randomly assigned adult patients with death (defined by an Acute Physiology Chronic Health Evaluation [APACHE II] score <25 or single-organ failure) receive intravenous infusion placebo (24 microg per kilogram body weight hour) 96 hours in double-blind, placebo-controlled,...
<h3>Importance</h3>Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS) from binding at the cell surface MD2-TLR4 receptor. LPS major component of outer membrane gram-negative bacteria and potent activator acute inflammatory response.<h3>Objective</h3>To determine if eritoran, TLR4 antagonist, would significantly reduce sepsis-induced mortality.<h3>Design, Setting, Participants</h3>We performed randomized, double-blind, placebo-controlled, multinational phase 3...
Preclinical studies suggest that exogenous surfactant may be of value in the treatment acute respiratory distress syndrome (ARDS), and two phase 2 clinical trials have shown a trend toward benefit. We conducted 3 protein-containing adults with ARDS.In multicenter, randomized, double-blind involving 448 patients ARDS from various causes, we compared standard therapy alone plus up to four intratracheal doses recombinant protein C-based given within period 24 hours.The overall survival rate was...
In Brief Background & Aims: patients with severe, necrotizing pancreatitis, it is common to administer early, broad-spectrum antibiotics, often a carbapenem, in the hope of reducing incidence pancreatic and peripancreatic infections, although benefits doing so have not been proved. Methods: A multicenter, prospective, double-blind, placebo-controlled randomized study set 32 centers within North America Europe. Participants: One hundred clinically confirmed pancreatitis: 50 received meropenem...
Abstract Introduction Altered pharmacokinetics (PK) in critically ill patients can result insufficient serum β-lactam concentrations when standard dosages are administered. Previous studies on PK have generally excluded the most severely patients, or were conducted during steady-state period of treatment. The aim our study was to determine whether first dose piperacillin-tazobactam, ceftazidime, cefepime, and meropenem would adequate drug with severe sepsis septic shock. Methods Open,...
Intensive care unit (ICU) survivors have reduced long-term survival compared to the general population. Identifying parameters at ICU discharge that are associated with poor outcomes may prove useful in targeting an at-risk The main objective of study was identify clinical and biological determinants death year following discharge. FROG-ICU a prospective, observational, multicenter cohort followed 1 after discharge, including 21 medical, surgical or mixed ICUs France Belgium. All consecutive...
BackgroundSARS-CoV-2 targets endothelial cells through the angiotensin-converting enzyme 2 receptor. The resulting injury induces widespread thrombosis and microangiopathy. Nevertheless, early specific markers of dysfunction vascular redox status in COVID-19 patients are currently missing.MethodsObservational study including ICU non-ICU adult admitted hospital for acute respiratory failure, compared with control subjects matched cardiovascular risk factors similar to patients, septic shock...
Passive immunization with plasma collected from convalescent patients has been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available regarding the use of in Covid-19-induced acute respiratory distress syndrome (ARDS).
Objective To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activated protein C, across clinically relevant subpopulations in randomized, phase 3, placebo-controlled study patients with severe sepsis (recombinant C worldwide evaluation [PROWESS]). Design Univariate and multivariable analysis prospectively defined subgroups from PROWESS study. Setting A total 164 medical centers 11 countries. Patients 1,690 sepsis. Measurements Main Results We report observed...
To assess the cost-effectiveness of drotrecogin alfa (activated) therapy, which was recently shown to reduce mortality in severe sepsis.Estimates effectiveness and resource use were based on data collected prospectively as part a multicenter international trial. Estimates hospital costs subset patients treated United States (33% all enrolled patients). Lifetime projections modeled from published sources tested sensitivity analyses. Analyses conducted societal perspective, limited healthcare...
Objective: To investigate community-acquired pneumonia (CAP) as a cause of severe sepsis in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation Severe Sepsis) trial and to evaluate effect drotrecogin alfa (activated) (DrotAA) this subgroup. Design: Retrospective analysis CAP subgroup trial. Setting: Tertiary care institutions 11 countries. Interventions: DrotAA (n = 850), 24 μg·kg−1·hr−1 for 96 hrs, or placebo 840). Participants: The 1,690 patients with enrolled...
Abstract Introduction It has been proposed that doses of amikacin >15 mg/kg should be used in conditions associated with an increased volume distribution (V d ), such as severe sepsis and septic shock. The primary aim this study was to determine whether 25 (total body weight) is adequate loading dose for these patients. Methods This open, prospective, multicenter four Belgian intensive care units (ICUs). All consecutive patients a diagnosis or shock, whom treatment indicated, were...
Norepinephrine, the first-line vasopressor for septic shock, is not always effective and has important catecholaminergic adverse effects. Selepressin, a selective vasopressin V1a receptor agonist, noncatecholaminergic that may mitigate sepsis-induced vasodilatation, vascular leakage, edema, with fewer To test whether selepressin improves outcome in shock. An adaptive phase 2b/3 randomized clinical trial comprising 2 parts included adult patients (n = 868) shock requiring more than 5 μg/min...
Abstract Background The optimal dosing of antibiotics in critically ill patients receiving renal replacement therapy (RRT) remains unclear. In this study, we describe the variability RRT techniques and antibiotic relate observed trough concentrations to targets. Methods We performed a prospective, observational, multinational, pharmacokinetic study 29 intensive care units from 14 countries. collected demographic, clinical, data. measured meropenem, piperacillin-tazobactam, vancomycin related...
Objectives: As the catabolic state induced by septic shock together with physical inactivity of patients lead to rapid loss muscle mass and impaired function, purpose this study was test whether an early therapy during onset regulates signals preserves skeletal mass. Design: Randomized controlled trial. Setting: Tertiary mixed ICU. Patients: Adult admitted for within first 72 hours. Interventions: Patients were assigned randomly into two groups. The control group benefited from manual...